• Home
  • NEW DAY MEDICINE
  • 5 (37) 2021
  • 31 -5 (37) 2021 — Bogatikova A.I., Kolomiets V.M. — THE RESULTS OF GENETIC TESTING AS RISK FACTORS FOR THE FAILURE OF ETIOTROPIC THERAPY OF TUBERCULOSIS

31 -5 (37) 2021 — Bogatikova A.I., Kolomiets V.M. — THE RESULTS OF GENETIC TESTING AS RISK FACTORS FOR THE FAILURE OF ETIOTROPIC THERAPY OF TUBERCULOSIS

THE RESULTS OF GENETIC TESTING AS RISK FACTORS FOR THE FAILURE OF ETIOTROPIC THERAPY OF TUBERCULOSIS

Bogatikova A.I., Kursk State Medical University of the Ministry of Health of Kursk

Kolomiets V.M. Kursk State Medical University of the Ministry of Health of Kursk

Resume

The publication presents the results of etiotropic therapy of tuberculosis patients, as risk factors for its failures, determined by individual genetic markers and environmental conditions. The study substantiates the need to test tuberculosis patients to determine the polymorphism of genes of xenobiotic biotransformation enzymes in order to predict the risk of failure of their etiotropic therapy.

Keywords. Genetic markers; etiotropic therapy; tuberculosis.

First page

105

Last page

107

For citation: Bogatikova A.I., Kolomiets V.M. THE RESULTS OF GENETIC TESTING AS RISK FACTORS FOR THE FAILURE OF ETIOTROPIC THERAPY OF TUBERCULOSIS //New Day in Medicine 5(37)2021 105-107 https://cutt.ly/2T8z7V0

LIST OF REFERENCES:

  1. Babushkina N.P. Mnogofaktornyye zabolevaniya i prodolzhitel’nost’ zhizni. / Med. genetika. -2015. №2. S.14.
  2. Bragina Ye.Yu., Tiys Ye.S., Freydin M.B., Koneva L.A., Ivanisenko V.A., Puzyrev V.P. Obshchiye geneticheskiye faktory razvitiya bronkhial’noy astmy i tuberkuloza. //Med. genetika. -2015. №2. S.29-30.
  3. Polonikov A.V. Polimorfizm genov fermentov biotransformatsii ksenobiotikov i ikh kompleksnoye vliyaniye na predraspolozhennost’ k mul’tifaktorial’nym zabolevaniyam. /Avtoref. diss. dokt., M., 2006. 38 s.
  4. Solovenchuk L.L. Geneticheskiye aspekty adaptatsii cheloveka k eks-tremal’nym usloviyam sredy /Nasledstvennost’ cheloveka i okruzhayushchaya sreda. M.: Nauka, 1992. – Vyp. 2. – S.35-54.
  5. Choi R, Jeong BH, Koh WJ, Lee SY. Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations. //Ann Lab Med. 2017 Mar;37(2):97-107.
  6. Cooper RS. Gene-environment interactions and the etiology of common complex disease //Ann. Intern. Med. 2003. – Vol.139. – P.437-440
  7. Matsumoto T, Ohno M, Azuma J. Future of pharmacogenetics-based therapy for tuberculosis. Pharmacogenomics. 2014 Apr;15(5):601-7.
  8. Nebert D.W., Carvan M.J. Ecogenetics: from biology to health //Toxi-col. Indust. Hlth. 1997. – Vol.13. -P.163-192.
  9. Risch N.J. Searching genetic determinants in the new millennium // Na-ture. -2000. Vol.405. – P.847-856.
  10. Weiss K.M., Terwilliger J.D. How many diseases does it take to map a gene with SNPs? // Nat. Genet. 2000. – Vol.26. – P. 151-157.

file

download